Division of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.
Chest. 2013 Nov;144(5):1622-1631. doi: 10.1378/chest.13-0394.
T1 (≤ 3 cm) tumors with visceral pleural invasion (VPI) are upstaged to T2a (stage IB) in the TNM classification. We investigated the effect of VPI on the cumulative incidence of recurrence (CIR) and overall survival (OS) of lung adenocarcinoma (ADC) ≤ 2 cm (T1a) and 2 to 3 cm (T1b).
OS and CIR among patients with or without VPI were examined by tumor size (≤ 2 and 2-3 cm) in 777 patients with node-negative lung ADC ≤ 3 cm who underwent resection.
Among patients with tumors ≤ 2 cm, VPI was not associated with either increased CIR (P = .90) or decreased OS (P = .11). Among patients with tumors 2 to 3 cm in size, the presence of VPI was associated with increased CIR (P = .015) and decreased OS (P < .001), even after adjusting for histologic subtype. When stage I lung ADCs ≤ 3 cm were regrouped as either new stage IA (≤ 2 cm with or without VPI, 2-3 cm without VPI) or new stage IB (2-3 cm with VPI), there was a statistically significant difference in 5-year CIR and OS between new stage IA and new stage IB tumors (CIR, 18% vs 40% [P = .004]; OS, 76% vs 51% [P < .001]).
VPI stratifies prognosis in patients with lung ADC 2 to 3 cm but not in those with tumors ≤ 2 cm. Our proposed regrouping of a new stage IB better stratifies patients with poor prognosis, similar to published outcomes in patients with stage II disease, who may benefit from adjuvant chemotherapy.
在 TNM 分期中,T1(≤3cm)肿瘤合并内脏胸膜侵犯(VPI)被升级为 T2a(IB 期)。我们研究了 VPI 对肺腺癌(ADC)≤2cm(T1a)和 2-3cm(T1b)患者累积复发率(CIR)和总生存率(OS)的影响。
对 777 例淋巴结阴性肺 ADC≤3cm 且行切除术的患者,根据肿瘤大小(≤2cm 和 2-3cm),检查 VPI 患者和无 VPI 患者的 OS 和 CIR。
在肿瘤≤2cm 的患者中,VPI 与 CIR 增加(P=0.90)或 OS 降低(P=0.11)无关。在肿瘤大小为 2-3cm 的患者中,VPI 与 CIR 增加(P=0.015)和 OS 降低(P < 0.001)相关,即使在调整组织学亚型后也是如此。当将≤3cm 的 I 期肺 ADC 重新分组为新的 IA 期(≤2cm 伴或不伴 VPI,2-3cm 无 VPI)或新的 IB 期(2-3cm 伴 VPI)时,新的 IA 期和新的 IB 期肿瘤的 5 年 CIR 和 OS 存在统计学显著差异(CIR,18%比 40%[P=0.004];OS,76%比 51%[P < 0.001])。
VPI 可对 2-3cm 的肺 ADC 患者进行预后分层,但不能对≤2cm 的肿瘤患者进行预后分层。我们提出的新的 IB 期分组可以更好地分层预后不良的患者,与 II 期疾病患者的发表结果相似,后者可能受益于辅助化疗。